OR WAIT null SECS
June 11, 2021
Immodulon has received an indication of allowability from the European Patent Office for the claims in its patent application relating to its lead drug candidate.
The CGT Catapult has formed a consortium aimed at advancing the technology development and lowering costs of cell and gene therapy manufacturing.
Researchers from the Chalmers University of Technology and AstraZeneca have developed a new method of detecting and testing lipid nanoparticles.
June 10, 2021
FDA’s approval of Biogen’s treatment for Alzheimer’s disease has raised questions about the agency’s accelerated approval process.
June 08, 2021
An ANDA from Sandoz for albuterol sulfate inhalation aerosol was approved by FDA.
The vaccine is now authorized for ages 12 and older in European Union member states and the UK.
The agency issued two final and two draft guidance documents to help identify and trace drug products in the supply chain.
FDA approved Ryplazim (plasminogen, human-tmvh) for the treatment of plasminogen deficiency type 1.
June 07, 2021
FDA has granted accelerated approval to Biogen for Aduhelm (aducanumab), a new mAb treatment for Alzheimer’ disease.
The Biden administration supports a notable increase in funding for public health and research as a lead priority for the coming year.